
Bulletin #34

Manitoba Drug Benefits and Interchangeability Formulary Amendments



Copies of the consolidated regulations for Pharmacare benefits and interchangeable drugs (including the enclosed amendments), will be available, along with a copy of this bulletin on the Internet on February 11, 2002.

<http://www.gov.mb.ca/health/mdbif>

The following changes will be made to the Pharmacare benefit list effective February 11, 2002.

Inside This Issue	
Part 1 Additions	Page 2 & 3
Part 2 Additions & Amendments	Page 3, 4 & 5
Part 3	Page 5 & 6
New Interchangeable Categories	Page 6, 7 & 8
New Interchangeable Products	Page 8, 9 & 10
Product Deletions	Page 10
Category Deletions	Page 11
Interchangeable Product Price Changes	Page 11, 12, 13, 14 & 15
Discontinued Products	Page 15, 16 & 17
Manufacturers' Update	Page 18
Health Canada Information	Page 19
Core Submission Requirements - Update	Page 19

Bulletin 34

Effective date February 11, 2002

Part 1 Additions

DIN	TRADE NAME	GENERIC	DOSAGE	FORM	MFG* ABB
00977999	Accu-Chek Compact	glucose test strip		Strip	ROC
00888230 00888206 00888214 00888222	A-Hydrocort	hydrocortisone sodium succinate	100 mg/vial 250 mg/vial 500 mg/vial 1000 mg/vial	Injection	ABB
02244166	Apo-Fluphenazine	fluphenazine decanoate	25 mg/mL	Injection	APX
02244304 02244305 02244306	Apo-Gabapentin	gabapentin	100 mg 300 mg 400 mg	Capsules	APX
02243827	Apo-Ipravent	ipratropium bromide	125 mcg/mL	Inhalation Solution Sterules	APX
02244022 02244023	Apo-Misoprostol	misoprostol	100 mcg 200 mcg	Tablets	APX
02243324 02243325	Apo-Propafenone	propafenone HCl	150 mg 300 mg	Tablets	APX
02242177 02242178	Co Fluoxetine	fluoxetine HCl	10 mg 20 mg	Capsules	RED
02243231	Dimethyl Sulfoxide	dimethyl sulfoxide	500 mg/g	Injection	SIL
02242920	Gen-Hydroxyurea	hydroxyurea	500 mg	Capsules	GPM
02236866 02242631	Haloperidol Long Acting	haloperidol decanoate	50 mg/mL 100 mg/mL	Injection	NOP
00872520 00872539 00878618 00878626	Hydrocortisone Sodium Succinate	hydrocortisone sodium succinate	100 mg/vial 250 mg/vial 500 mg/vial 1000 mg/vial	Injection	NOP
02244350 02244351 02244352	Nu-Pravastatin	pravastatin sodium	10 mg 20 mg 40 mg	Tablets	NXP
00906922	Penlet Plus Adjustable Blood Sampler	glucose test strip		Strip	LIF

Bulletin 34

Effective date February 11, 2002

02244138 02244139 02244140	pms-Divalproex	divalproex sodium	125 mg 250 mg 500 mg	Enteric Coated Tablets	PMS
00728187 00728195 00728209	pms-Lorazepam	lorazepam	0.5 mg 1 mg 2 mg	Tablets	PMS
00900303	Sof-tact	glucose test strips		Strips	ABB
00030600 00030619 00030627 00030635	Solu-Cortef	hydrocortisone sodium succinate	100 mg/vial 250 mg/vial 500 mg/vial 1000 mg/vial	Injection	PNU
00550507	Triacomb	neomycin- gramicidin-nystatin- triamcinolone	2.5 mg-0.25 mg - 100,000 U-1 mg/g	Topical Cream	TCH
00901556	Ultra Soft Lancet	lancets			LIF

* Abbreviation of Manufacturers' Names

Part 2 Additions and Amendments

• Alti-Cefuroxime	cefuroxime axetil	250 mg 500 mg	Tablets	ALT
--------------------------	-------------------	------------------	---------	-----

- (a) Step-down care following hospital separation in patients treated with intravenous cephalosporins;
- (b) Treatment of patients with infections not responding to alternative antibiotics (eg. amoxicillin);
- (c) Treatment of infections caused by organisms known to be resistant to alternative antibiotics (eg. amoxicillin);
- (d) Treatment of patients known to be allergic or unresponsive to alternative antibiotics (eg. penicillin or sulfonamides).

• Apo-Amoxi Clav	amoxicillin, potassium clavulanate	25/6.25 mg 50/12.5 mg	Suspension	APX
-------------------------	--	--------------------------	------------	-----

Bulletin 34

Effective date February 11, 2002

- (a) For treatment of patients not responding to alternative antibiotics (eg. amoxicillin);
- (b) For treatment of patient with infections caused by organisms known to be resistant to alternative antibiotics (eg. amoxicillin).

• Apo-Cefuroxime	cefuroxime	250 mg 500 mg	Tablets	APX
-------------------------	------------	------------------	---------	-----

- (e) Step-down care following hospital separation in patients treated with intravenous cephalosporins;
- (f) Treatment of patients with infections not responding to alternative antibiotics (eg. amoxicillin);
- (g) Treatment of infections caused by organisms known to be resistant to alternative antibiotics (eg. amoxicillin);
- (h) Treatment of patients known to be allergic or unresponsive to alternative antibiotics (eg. penicillin or sulfonamides).

- The criteria for **Climara, Estalis, Estracomb, Estraderm, Estrogel, Oesclim** and **Vivelle** have been revised as follows:
 - For patients:
 - (a) who are smokers (current);
 - (b) with increased triglycerides;
 - (c) with a history of cholelithiasis; or
 - (d) who cannot tolerate oral estrogens due to intolerable side effects (eg. GI upset, irregular bleeding, etc) or who cannot take any medications by mouth. Patients should have tried at least two different oral estrogen products (eg. Premarin, Estrace, Ogen).
- The criteria for **Duragesic** has been revised as follows:
 - For treatment of pain in patients unable to tolerate oral analgesics or when there is failure to adequately control pain with oral analgesics or in patients in whom oral analgesics are deemed inappropriate.

• Rhoxal-ticlopidine	ticlopidine HCl	250 mg	Tablets	RXP
-----------------------------	--------------------	--------	---------	-----

- Rhoxal-ticlopidine will be reimbursed for patients:
 - (a) For the secondary prevention of vascular ischemic events ie. myocardial infarction, or stroke

Bulletin 34

Effective date February 11, 2002

- (i) who are known to be or become intolerant to ASA, or
- (ii) who continue to have TIA or stroke symptoms or myocardial infarction while being treated with ASA or clopidogrel.

NOTE: ASA should be first line for the secondary prevention of vascular ischemic events such as myocardial infarction or stroke. Before abandoning ASA, efforts should be made to improve tolerability of ASA by reducing the dose, taking it with food and using enteric coated ASA.

(b) Post coronary stent implantation x 28 days in combination with ASA.

Part 3

The following products will be considered for Pharmacare reimbursement upon an individual prescriber/patient request basis.

• Apo-Oxaprozin	oxaprozin	600 mg	Tablets	APX
------------------------	-----------	--------	---------	-----

- Where at least two other non-steroid anti-inflammatory drugs (NSAIDs) have been tried and failed or were not tolerated.

• Rapamune	sirolimus	1 mg/mL	Oral Solution	WAY
-------------------	-----------	---------	---------------	-----

- For transplant patients who are experiencing:

- (a) Ongoing rejection despite maximally tolerated therapy with other agents (ex. CsA, MMF, tacrolimus). Rapamune would be added to existing therapy.
- (b) Acute or chronic calcineurin inhibitor related side effects (nephrotoxicity, neurotoxicity, etc). Rapamune would be added to existing therapy in an attempt to decrease doses of calcineurin inhibitors.

NOTE: Rapamune should not be used for monotherapy or first line therapy.

• Renagel	sevelamer HCl	400 mg 800 mg	Tablets	GZY
------------------	---------------	------------------	---------	-----

Upon the prescription of a nephrologist within the Provincial Dialysis Program, for control of hyperphosphatemia (> 1.8 mmol / L) where increased calcium carbonate is not warranted due to :

Bulletin 34

Effective date February 11, 2002

- A. Hypercalcemia, with ionized calcium >1.35 mmol/L or total calcium >2.65 mmol / L despite reduction in calcium carbonate dose and change of calcium in dialysis bath to 1.2 mmol / L ; OR, inability to utilize or increase calcium carbonate in the dialysis bath due to unacceptable hypercalcemia.
OR
- B. Clinically relevant soft tissue calcification based upon nephrologist's evaluation. Incidental calcification noted on x-ray is NOT an indication.
OR
- C. Calcium carbonate intolerance defined as unequivocal inability to utilize or increase calcium carbonate in order to maintain serum phosphate levels < 1.8 mmol/L.
OR
- D. Excessive calcium carbonate intake, defined as patient required to take in excess of 18 calcium carbonate 250 mg tablets per day.

Drug reviewed but not recommended for Pharmacare reimbursement at this time:

• Tamiflu	oseltamivir phosphate	75 mg	Capsules
------------------	-----------------------	-------	----------

New Interchangeable Categories

The following new interchangeable categories and products were added:

• Generic Name			
DIN	Trade Name	Manufacturer	Price in Cents

• Amoxicillin/Clavulanic Acid - 25/6.25 - Oral Suspension			
01916882	Clavulin 125 F	GSK	10.86
02243986	Apo-Amoxi Clav	APX	7.95

• Amoxicillin/Clavulanic Acid - 50/12.5 - Oral Suspension			
01916874	Clavulin 250 F	GSK	18.24
02243987	Apo-Amoxi Clav	APX	13.40

• Cefuroxime Axetil - 250 mg - Tablets			
02212277	Ceftin	GSK	144.73

Bulletin 34

Effective date February 11, 2002

02244393	Apo-Cefuroxime	APX	111.45
02242656	Alti-Cefuroxime	ALT	101.32

- Cefuroxime Axetil - 500 mg - Tablets

02212285	Ceftin	GSK	286.73
02244394	Apo-Cefuroxime	APX	220.80
02242657	Alti-Cefuroxime	ALT	200.72

- Dimethyl Sulfoxide - 500 mg/g - Injection

00493392	Rimso-50	SHI	122.10
02243231	Dimethyl Sulfoxide	SIL	109.89

- Hydroxyurea - 500 mg - Capsules

00465283	Hydrea	SQU	124.71
02242920	Gen-Hydroxyurea	GPM	124.71

- Loratadine - 10 mg - Tablets

00782696	Claritin	SCH	91.92
02243880	Apo-Loratadine	APX	68.95

- Midazolam HCl - 1 mg/mL - Injection

00784516	Versed	HLR	78.65
02243253	Apo-Midazolam	APX	59.00

- Midazolam HCl - 5 mg/mL - Injection

00766011	Versed	HLR	336.60
02243254	Apo-Midazolam	APX	252.50

- Misoprostol - 100 mcg - Tablets

00813966	Cytotec	PMJ	29.92
02244022	Apo-Misoprostol	APX	20.95

- Misoprostol - 200 mcg - Tablets

00632600	Cytotec	PMJ	49.81
02244023	Apo-Misoprostol	APX	34.90

- Oxaprozin - 600 mg - Tablets

02027860	Daypro	PMJ	71.50
----------	--------	-----	-------

Bulletin 34

Effective date February 11, 2002

02243661	Apo-Oxaprozin	APX	53.65
----------	---------------	-----	-------

• Zidovudine - 100 mg - Capsules			
01902660	Retrovir	GSK	170.00
01946323	Apo-Zidovudine	APX	132.00
01953877	Novo-AZT	NOP	132.00

New Interchangeable Products

The following products have been added to existing interchangeable drug categories:

Price in
Cents

• Divalproex Sodium - 125 mg - Enteric Coated Tablets			
02244138	pms-Divalproex	PMS	16.83

• Divalproex Sodium - 250 mg - Enteric Coated Tablets			
02244139	pms-Divalproex	PMS	30.25

• Divalproex Sodium - 500 mg - Enteric Coated Tablets			
02244140	pms-Divalproex	PMS	60.53

• Fluphenazine Decanoate - 25 mg/mL - Injection			
02244166	Apo-Fluphenazine	APX	\$5.10

• Fluoxetine - 10 mg - Capsules			
02242177	Co Fluoxetine	RED	129.51

• Fluoxetine - 20 mg - Capsules			
02242178	Co Fluoxetine	RED	111.24

• Gabapentin - 100 mg - Capsules			
02244304	Apo-Gabapentin	APX	30.80

• Gabapentin - 300 mg - Capsules			
02244305	Apo-Gabapentin	APX	**74.90

Bulletin 34

Effective date February 11, 2002

• Gabapentin - 400 mg - Capsules			
02244306	Apo-Gabapentin	APX	89.30
• Haloperidol Decanoate - Long Acting Injection - 50 mg/mL			
00599085	Haldol LA	JAN	\$9.28
02236866	Haloperidol Long Acting	NOP	**\$5.61
• Haloperidol Decanoate - Long Acting Injection - 100 mg/mL			
00599093	Haldol LA	JAN	\$18.33
02242631	Haloperidol Long Acting	NOP	**\$11.08
• Ipratropium Bromide - 125 mcg/mL - Unit Dose Vial			
02243827	Apo-Ipravent	APX	**41.50
• Lorazepam - 0.5 mg - Oral Tablets			
00728187	pms-Lorazepam	PMS	**5.14
• Lorazepam - 1 mg - Oral Tablets			
00728195	pms-Lorazepam	PMS	**5.24
• Lorazepam - 2 mg - Oral Tablets			
00728209	pms-Lorazepam	PMS	**8.51
• Neomycin-Gramicidin-Nystatin-Triamcinolone - 2.5 mg-0.25 mg-100,000 U-1 mg/g - Topical Cream			
00550507	Triacomb	TCH	**43.01
• Pravastatin Sodium - 10 mg - Tablets			
02244350	Nu-Pravastatin	NXP	**95.34
• Pravastatin Sodium - 20 mg - Tablets			
02244351	Nu-Pravastatin	NXP	**112.46
• Pravastatin Sodium - 40 mg - Tablets			
02244352	Nu-Pravastatin	NXP	**135.45
• Propafenone HCl - 150 mg - Tablets			
02243324	Apo-Propafenone	APX	**74.95
• Propafenone HCl - 300 mg - Tablets			

Bulletin 34

Effective date February 11, 2002

02243325	Apo-Propafenone	APX	**132.15
• Ticlopidine HCl - 250 mg - Tablets			
02243587	Rhoxal-ticlopidine	RXP	75.74

** The price change has resulted in a change to the lowest price in the category.

() Denotes the price of the lowest generic product in the product category.

Product Deletions

The following products have been deleted:

02004844	Virostat	edoxudine	3%	Cream
00261327	Bisacolax	bisacodyl	10 mg	Suppositories
00580988	Chlorpromanyl 20	chlorpromazine	20 mg/mL	Oral Liquid
00791172	Decongest	xylometazoline HCl	0.1%	Nasal Spray
02042606	Isordil	isosorbide dinitrate	5 mg	Sublingual Tablets
02134861	Miocarpine	pilocarpine HCl	1%	Ophthalmic Solution (20.54)
02134888	Miocarpine	pilocarpine HCl	2%	Ophthalmic Solution (22.81)

Category Deletions

The following categories have been deleted:

- Chlorpromazine - 20 mg/mL/Oral Liquid
- Diltiazem HCl - 60 mg - Sustained Release Capsules
- Diltiazem HCl - 90 mg - Sustained Release Capsules

Bulletin 34

Effective date February 11, 2002

- Isosorbide Dinitrate - 5 mg - Sublingual Tablets
- Xylometazoline HCl - 0.1% - Nasal Spray

Interchangeable Product Price Changes

The following changes in prices have occurred:

00545015	Apo-Acetazolamide	acetazolamide	250 mg	Tablets	**9.35
00335053	Apo-Amitriptyline	amitriptyline HCl	10 mg	Tablets	**5.20
00335061	Apo-Amitriptyline	amitriptyline HCl	25 mg	Tablets	**9.95
00335088	Apo-Amitriptyline	amitriptyline HCl	50 mg	Tablets	**18.50
00754129	Apo-Amitriptyline	amitriptyline HCl	75 mg	Tablets	**21.90
00754595	Apo-Bisacodyl	bisacodyl	10 mg	Suppository	54.50
00618454	Apo-Chlorax	chlordiazepoxide HCl	5/2.5 mg	Capsules	20.20
00360279	Apo-Chlorthalidone	chlorthalidone	50 mg	Tablets	**7.85
00405329	Apo-Diazepam	diazepam	2 mg	Tablets	**6.10
00362158	Apo-Diazepam	diazepam	5 mg	Tablets	**9.00
00405337	Apo-Diazepam	diazepam	10 mg	Tablets	**10.40
00363766	Apo-Dimenhydrinate	dimenhydrinate	50 mg	Tablets	**1.35 (1.27)
00545031	Apo-Ferrous Gluconate	ferrous gluconate	300 mg	Tablets	**2.55 (2.50)
00426849	Apo-Folic	folic acid	5 mg	Tablets	**2.35
00396788	Apo-Furosemide	furosemide	20 mg	Tablets	**4.45
00362166	Apo-Furosemide	furosemide	40 mg	Tablets	**6.70
00326844	Apo-Hydro HCT	hydrochlorothiazide	25 mg	Tablets	**4.75
00312800	Apo-Hydro HCT	hydrochlorothiazide	50 mg	Tablets	**6.60
00312797	Apo-Imipramine	imipramine HCl	25 mg	Tablets	**16.50
00326852	Apo-Imipramine	imipramine HCl	50 mg	Tablets	**30.65
00360260	Apo-Methyldopa	methyldopa	250 mg	Tablets	**14.00
00426830	Apo-Methyldopa	methyldopa	500 mg	Tablets	**21.25
00441708	Apo-Methazide-15	methyldopa-hydrochlorothiazide	250/15 mg	Tablets	**16.80
00441716	Apo-Methazide-25	methyldopa-hydrochlorothiazide	250/25 mg	Tablets	**18.35
00402745	Apo-Oxazepam	oxazepam	15 mg	Tablets	**6.60
00402737	Apo-Oxazepam	oxazepam	30 mg	Tablets	**9.00
00312770	Apo-Prednisone	prednisone	5 mg	Tablets	**2.60
00550957	Apo-Prednisone	prednisone	50 mg	Tablets	**10.95
00441740	Apo-Quinidine	quinidine sulfate	200 mg	Tablets	**11.00
00441759	Apo-Sulfinpyrazone	sulfinpyrazone	100 mg	Tablets	**14.00

Bulletin 34

Effective date February 11, 2002

00580929	Apo-Tetra	tetracycline	250 mg	Capsules	6.35
00312762	Apo-Tolbutamide	tolbutamide	500 mg	Tablets	**8.25
00293504	Atasol-15	acetaminophen compound with codeine	15 mg	Tablets	9.32
00293512	Atasol-30	acetaminophen compound with codeine	30 mg	Tablets	15.52
00068756	Coactifed	triprolidine HCl/pseudoephedrine HCl/guaifenesin/ codeine phosphate	2 mg/30 mg/100 mg/10 mg per 5 mL	Expectorant	6.90
01912828	Cortisporin	polymyxin/neomycin/ hydrocortisone	10,000 Units/3.5 mg/10 mg	Otic Solution	114.50
02213265	Dermovate	clobetasol-17 propionate	0.05%	Cream	74.93
02213273	Dermovate	clobetasol-17 propionate	0.05%	Ointment	74.93
02213281	Dermovate	clobetasol-17 propionate	0.05%	Scalp Lotion	72.20
00666130	Empracet-30	acetaminophen with codeine	300 mg-30 mg	Tablets	**4.55
00666149	Empracet-60	acetaminophen with codeine	300 mg-60 mg	Tablets	**14.16
02145758	Gentamicin Sulfate	gentamicin sulfate	40 mg/mL	Injection	**217.80
00004596	Imuran	azathioprine	50 mg	Tablets	86.00
01918303	K-10	potassium chloride	1.33 mEq/mL	Oral Liquid	1.44
00004758	Kemadrin	procyclidine HCl	5 mg	Tablets	**2.55
00004405	Kemadrin	procyclidine HCl	2.5 mg/5 mL	Oral Liquid	**3.07
02036290	Monitan	acebutolol HCl	100 mg	Tablets	28.47
02036436	Monitan	acebutolol HCl	200 mg	Tablets	42.60
02036444	Monitan	acebutolol HCl	400 mg	Tablets	84.65
02170698 Old din 00014915	Methotrexate	amethopterin	2.5 mg	Tablets	**77.41
00666122	Neosporin	polymyxin B sulfate - neomycin sulfate-zinc bacitracin	5,000 U-5 mg-400 U/g	Topical Ointment	41.00
00694398	Neosporin	polymyxin B sulfate- neomycin sulfate-zinc bacitracin	10,000 U-5 mg-400 U/g	Ophthalmic Ointment	214.29
02231691	Novo-Cefaclor	cefaclor	250 mg	Capsules	**70.73

Bulletin 34
Effective date February 11, 2002

02231693	Novo-Cefaclor	cefaclor	500 mg	Capsules	**138.88
02235134	Novo-Cefadroxil	cefadroxil	500 mg	Capsules	**92.63 (92.60)
02242538	Novo-Diltazem CD	diltiazem HCl	120 mg	Controlled Delivery Capsules	**88.23
02242539	Novo-Diltazem CD	diltiazem HCl	180 mg	Controlled Delivery Capsules	**117.11
02242540	Novo-Diltazem CD	diltiazem HCl	240 mg	Controlled Delivery Capsules	**155.33
02242541	Novo-Diltazem CD	diltiazem HCl	300 mg	Controlled Delivery Capsules	**194.17
02239701	Novo-Divalproex	divalproex sodium	125 mg	Enteric Coated Tablets	**16.83 (16.80)
02239702	Novo-Divalproex	divalproex sodium	250 mg	Enteric Coated Tablets	**30.25
02239703	Novo-Divalproex	divalproex sodium	500 mg	Enteric Coated Tablets	**60.53 (60.50)
02243551	Novo-Fenofibrate	fenofibrate	67 mg	Capsules	**47.58
02243552	Novo-Fenofibrate	fenofibrate	200 mg	Capsules	**119.79
00021474	Novo-Hydrazide	hydrochlorothiazide	25 mg	Tablets	5.23
00021482	Novo-Hydrazide	hydrochlorothiazide	50 mg	Tablets	**7.15 (6.60)
02243312	Novo-Naproxen EC	naproxen	250 mg	Enteric Coated Tablets	**31.19
02243313	Novo-Naproxen EC	naproxen	375 mg	Enteric Coated Tablets	**40.55 (40.43)
02243314	Novo-Naproxen EC	naproxen	500 mg	Enteric Coated Tablets	**75.83
00021695	Novo-Prednisone	prednisone	5 mg	Tablets	**2.86 (2.60)
00337730	Novo-Semide	furosemide	20 mg	Tablets	**4.90 (4.45)

Bulletin 34
Effective date February 11, 2002

00337749	Novo-Semide	furosemide	40 mg	Tablets	**7.37 (6.70)
00765953	Novo-Semide	furosemide	80 mg	Tablets	**13.42
02240346	Novo-Terbinafine	terbinafine HCl	250 mg	Tablets	**277.70 (259.27)
02100630	Novo-Valproic	valproic acid	250 mg	Capsules	**28.42 (28.40)
02218321	Novo-Valproic	valproic acid	500 mg	Enteric Coated Capsules	**57.17
00717509	Nu-Medopa	methyldopa	250 mg	Tablets	14.00
00717576	Nu-Medopa	methyldopa	500 mg	Tablets	21.25
02045680	Nu-Sulfinpyrazone	sulfinpyrazone	100 mg	Tablets	14.00
02045699	Nu-Sulfinpyrazone	sulfinpyrazone	200 mg	Tablets	19.80
00717606	Nu-Tetra	tetracycline HCl	250 mg	Capsules	**6.35
02231780	pms-Fenofibrate Micro	fenofibrate	200 mg	Capsules	119.79
02083531	Relafen	nabumetone	500 mg	Tablets	69.01
02083558	Relafen	nabumetone	750 mg	Tablets	93.73
00270644	Septra	trimethoprim-sulfamethoxazole	40 mg-200 mg/5 mL	Oral Suspension	**1.99
00270636	Septra	trimethoprim-sulfamethoxazole	80 mg-400 mg	Tablets	**4.82
00368040	Septra DS	trimethoprim-sulfamethoxazole	160 mg-800 mg	Tablets	**12.22
02213478	Ventolin	salbutamol	200 dose-0.100 mg/dose	Inhalation Aerosol	6.14
02213419	Ventolin PF	salbutamol sulfate	2.5 mg/2.5 mL	Unit Dose Solution Nebules	38.62
02213427	Ventolin	salbutamol sulfate	5 mg/2.5 mL	Unit Dose Solution Nebules	73.38
02213400	Ventolin	salbutamol sulfate	1.25 mg/2.5 mL	Unit Dose Solution Nebules	19.90
02213486	Ventolin	salbutamol	5 mg/mL	Respirator Solution	93.70
00013765	Vivol	diazepam	5 mg	Tablets	9.65
00013773	Vivol	diazepam	10 mg	Tablets	15.82
02212331	Zantac	ranitidine HCl	150 mg	Tablets	109.53

Bulletin 34

Effective date February 11, 2002

02212358	Zantac	ranitidine HCl	300 mg	Tablets	206.20
00634506	Zovirax	acyclovir	200 mg	Tablets	117.10
01911627	Zovirax	acyclovir	400 mg	Tablets	230.50
01911635	Zovirax	acyclovir	800 mg	Tablets	453.28
00004588	Zyloprim	allopurinol	100 mg	Tablets	10.15
00506370	Zyloprim	allopurinol	200 mg	Tablets	16.85
00294322	Zyloprim	allopurinol	300 mg	Tablets	27.54

****The price change has resulted in a change to the lowest price in the category.**

() Denotes the price of the lowest generic product in the product category.

Discontinued Products

Notice has been received from the manufacturer that the following products have been discontinued. They will be deleted with the next Formulary amendments.

02155885	Adalat PA	nifedipine	10 mg	Prolonged Action Tablets
02155893	Adalat PA	nifedipine	20 mg	Prolonged Action Tablets
02229707	Alti-Acyclovir	acyclovir	200 mg	Tablets
02229708	Alti-Acyclovir	acyclovir	400 mg	Tablets
02167808	Alti-Bromazepam	bromazepam	1.5 mg	Tablets
02167816	Alti-Bromazepam	bromazepam	3 mg	Tablets
00878723	Alti-Clobetasol Propionate	clobetasol-17 propionate	0.05%	Cream
00881678	Alti-Clobetasol Propionate	clobetasol-17 propionate	0.05%	Ointment
00878707	Alti-Clobetasol Propionate	clobetasol-17 propionate	0.05%	Scalp Lotion
01948776	Alti-Desipramine HCl	desipramine HCl	10 mg	Tablets
02140039	Alti-Doxycycline	doxycycline	100 mg	Capsules
00675202	Alti-Flurbiprofen	flurbiprofen	50 mg	Tablets
02218429	Alti-Moclobemide	moclobemide	300 mg	Tablets
02139952	Alti-Piroxicam	piroxicam	10 mg	Capsules
02139960	Alti-Piroxicam	prioxicam	20 mg	Capsules

Bulletin 34

Effective date February 11, 2002

02139979	Alti-Prazosin	prazosin	1 mg	Tablets
02194422	Alti-Ticlopidine	ticlopidine HCl	250 mg	Tablets
00614351	Alti-Triazolam	triazolam	0.125 mg	Tablets
00614378	Alti-Triazolam	triazolam	0.25 mg	Tablets
00867365	Alti-Verapamil	verapamil HCl	80 mg	Tablets
00867373	Alti-Verapamil	verapamil HCl	120 mg	Tablets
02041308	Amoxil	amoxicillin	500 mg	Capsules
02194082	Aristocort	triamcinolone	2 mg	Tablets
02231430	Asmavent	sabutamol sulfate	2.5 mg/2.5 mL	Unit Dose Solution Nebules
02134853	Atropisol	atropine sulfate	1%	Ophthalmic Solution
02237861	Capril	captopril	12.5 mg	Tablets
02237862	Capril	captopril	25 mg	Tablets
02237863	Capril	captopril	50 mg	Tablets
02237864	Capril	captopril	100 mg	Tablets
02217414	Deproic	valproic acid	250 mg	Capsules
02231489	Deproic	valproic acid	500 mg	Enteric Coated Capsules
01919547	Dyazide	triamterene- hydrochlorothiazide	50 mg-25 mg	Tablets
00880191	Garatec	gentamicin sulfate	5 mg/mL	Ophthalmic Solution
00880205	Garatec	gentamicin sulfate	5 mg/mL	Otic Solution
02239319	Gen-Etodolac	etodolac	200 mg	Capsules
02239320	Gen-Etodolac	etodolac	300 mg	Capsules
02240849	Gen- Fluvoxamine	fluvoxamine maleate	50 mg	Tablets
02240850	Gen- Fluvoxamine	fluvoxamine maleate	100 mg	Tablets
02243431	Gen-Naproxen EC	naproxen	250 mg	Enteric Coated Tablets
00013781 Old din 02241794 New din	Honvol	diethylstilbestrol diphosphate	100 mg	Tablets
01934147	Indotec	indomethacin	50 mg	Suppositories
02042614	Isordil	isosorbide dinitrate	30 mg	Tablets
02170035	Loxapac	loxapine succinate	50 mg	Tablets

Bulletin 34

Effective date February 11, 2002

02170655	Methotrexate	methotrexate	20 mg/mL	Injection
00624268	M.O.S.-10	morphine HCl	10 mg	Suppositories
00624276	M.O.S.-20	morphine HCl	20 mg	Suppositories
00636681	M.O.S.-30	morphine HCl	30 mg	Suppositories
00288217	Nadostine	nystatin	100,000 U/g	Topical Cream
00288195	Nadostine	nystatin	100,000 U/g	Topical Ointment
00288209	Nadostine	nystatin	25,000 U/g	Vaginal Cream
02229862	Orcipren	orciprenaline sulfate	2 mg/mL	Syrup
02229393	Pilocarpine	pilocarpine HCl	1%	Ophthalmic Solution
02229394	Pilocarpine	pilocarpine HCl	2%	Ophthalmic Solution
02229395	Pilocarpine	pilocarpine HCl	4%	Ophthalmic Solution
02043343	Phospholine Iodide	echothiophate iodide	12.5 mg/5 mL	Injection
02222035	Serc	betahistine dihydrochloride	4 mg	Tablets
01916815	Tagamet	cimetidine	300 mg	Tablets
01916785	Tagamet	cimetidine	400 mg	Tablets
01916777	Tagamet	cimetidine	600 mg	Tablets
02238708	Tomycine	tobramycin	0.3%	Ophthalmic Solution

Manufacturer Updates

- Please note that Abbott Laboratories Limited has acquired the operation of Knoll Pharma Inc. All Knoll products are now listed under Abbott Laboratories Limited (ABB).
- Please note that Bristol-Myers Squibb has acquired DuPont Pharmaceuticals. All products previously supplied by Dupont Pharma have been transferred to Bristol-Myers Squibb.

Bulletin 34

Effective date February 11, 2002

The following products have been transferred to Asta Medica (ATA)

NEW DIN	OLD DIN	Current Brand Name	Generic	Dosage	Form
02241793	00013587	Honvol Ampoules	diethylstilbestrol diphosphate	250 mg/5 mL	Liquid
02241795	00262676	Procytox	cyclophosphamide	25 mg	Tablets
02241796	00013749	Procytox	cyclophosphamide	50 mg	Tablets

The following products have been transferred to Clay-Park Labs Inc. (CPK)

DIN	Current Brand Name	Generic	Dosage	Form
02154862	Tridesilon	desonide	0.05%	Topical Cream
02154870	Tridesilon	desonide	0.05%	Ointment

The following product has been transferred to Lifehealth Limited (LHL)

DIN	Current Brand Name	Generic	Dosage	Form
02199270	Nitoman	tetrabenazine	25 mg	Tablets

The following products have new DINS:

NEW DIN	OLD DIN	Current Brand Name	Generic
02194031	00127914	Aristocort R	triamcinolone acetonide
02242374	00591548	Pancrease	lipase/amylase/protease
02170698	00014915	Alti-Methotrexate	amethopterin

Please note the following Health Canada information

On November 30, 2001 Health Canada issued an Advisory titled "Important Safety Reminder for Patients taking Oral Diabetes Drugs of the Glitazone class, Avandia® and Actos®." In the advisory, it was stated "In Canada, Actos® and Avandia® are not approved for use in combination with insulin, where these safety concerns may be more frequent." This information may be accessed on the Internet at:

http://www.hc-sc.gc.ca/english/protection/warnings/2001/2001_132e.htm

Bulletin 34

Effective date February 11, 2002

On November 13, 2001 the manufacturer sent a "Dear Health Care Professional" letter to health care workers to explain this concern. This information can be accessed on the Internet at:

http://www.hc-sc.gc.ca/hpb-dgps/therapeut/zfiles/english/advisory/industry/avandia_e.html

Manufacturer Core Drug Submission Requirements for Manitoba - Update

Please note that the Authorization Letter used by industry (Template) to allow Manitoba Health to share information with other stakeholders now includes The Canadian Coordinating Office for Health Technology Assessment (CCOHTA).

Authorization Letter (Template)

Date:

To: Manitoba Health c/o Mr. Jack Rosentreter

Reference: (drug name, strength and dosage form)

This letter authorizes Manitoba Health to gain access to all information with respect to the product in the possession of the Health Protection Branch of Health Canada, the government of any province or territory in Canada, or the Patented Medicine Prices Review Board; and authorizes the Minister to disclose any information with respect to the product in the possession of Manitoba Health to the Health Protection Branch, to the government of a province or territory in Canada, to The Canadian Coordinating Office for Health Technology Assessment (CCOHTA), to a Regional Health Authority in Manitoba established under The Regional Health Authority Act, or to the Patented Medicine Prices Review Board.

(signature)

(Name and Title of Senior Company Official)